



4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-1346]

Development of Antiviral Drugs for the Treatment of Adenoviral Infection in

Immunocompromised Patients; Public Workshop; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration is announcing the cancellation of a public workshop entitled “Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients” that was previously scheduled for August 8, 2019, from 8:30 a.m. to 4:30 p.m. This public workshop was announced in the *Federal Register* of May 2, 2019. The meeting has been cancelled due to unforeseen changes in the adenovirus drug development landscape.

FOR FURTHER INFORMATION CONTACT: Lori Benner and/or Jessica Barnes, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6221, Silver Spring, MD 20993-0002, 301-796-1300, about this public workshop, which was announced in the *Federal Register* of May 2, 2019 (84 FR 18848).

Dated: July 8, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

[FR Doc. 2019-14887 Filed: 7/11/2019 8:45 am; Publication Date: 7/12/2019]